Want to see NEO full AI Analyst Report?

NeoGenomics (NEO) Stock Forecast & Price Target

1,952 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NEO Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

NeoGenomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NEO Stock 12 Month Forecast

Average Price Target

$21.50

▲(23.78% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for NeoGenomics in the last 3 months. The average price target is $21.50 with a high forecast of $28.00 and a low forecast of $19.00. The average price target represents a 23.78% change from the last price of $17.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","29":"$29","11.75":"$11.75","17.5":"$17.5","23.25":"$23.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,11.75,17.5,23.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.78,18.566153846153846,19.352307692307694,20.138461538461538,20.924615384615386,21.71076923076923,22.49692307692308,23.283076923076923,24.06923076923077,24.855384615384615,25.641538461538463,26.427692307692308,27.213846153846156,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.78,18.066153846153846,18.352307692307694,18.638461538461538,18.924615384615386,19.21076923076923,19.49692307692308,19.783076923076923,20.06923076923077,20.355384615384615,20.641538461538463,20.927692307692308,21.213846153846156,{"y":21.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.78,17.873846153846156,17.96769230769231,18.06153846153846,18.155384615384616,18.24923076923077,18.343076923076925,18.436923076923076,18.53076923076923,18.624615384615385,18.71846153846154,18.81230769230769,18.906153846153845,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.715,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.44,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.44,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.97,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.29,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.45,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.78,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$28.00

Average Price Target$21.50

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lu Li

Bank of America Securities

―

Hold

―

Reiterated

10/07/26

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (NYSE: JNJ) and NeoGenomics (NASDAQ: NEO)

Matt Larew

William Blair

―

Hold

―

Reiterated

10/06/26

Analysts Conflicted on These Healthcare Names: Regeneron (NASDAQ: REGN) and NeoGenomics (NASDAQ: NEO)

David Westenberg

Piper Sandler

$21

Buy

20.90%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

Mark Massaro

BTIG

$28

Buy

61.20%

Upside

Upgraded

10/06/26

NeoGenomics upgraded to Buy from Neutral at BTIGNeoGenomics upgraded to Buy from Neutral at BTIG

Michael Matson

Needham

$19→$22

Buy

26.66%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), AbbVie (ABBV)

Bruce Jackson

StoneX

$16→$20

Buy

15.14%

Upside

Reiterated

10/06/26

StoneX Sticks to Their Buy Rating for NeoGenomics (NEO)

William Bonello

Craig-Hallum

$17→$19

Buy

9.38%

Upside

Reiterated

07/29/26

NeoGenomics price target raised to $19 from $17 at Craig-HallumNeoGenomics price target raised to $19 from $17 at Craig-Hallum

Daniel Brennan

TD Cowen

$19

Buy

9.38%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Unknown Analyst

Stephens

Not Ranked

Stephens

$15.5

Buy

-10.77%

Downside

Reiterated

04/29/26

NeoGenomics (NEO) Receives a Buy from Stephens

Puneet Souda

Leerink Partners

$25

Buy

43.93%

Upside

Upgraded

04/29/26

NeoGenomics upgraded to Outperform from Market Perform at LeerinkNeoGenomics upgraded to Outperform from Market Perform at Leerink

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$15

Buy

-13.64%

Downside

Reiterated

02/18/26

Jefferies Sticks to Their Buy Rating for NeoGenomics (NEO)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

02/17/26

NeoGenomics (NEO) Receives a Hold from Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lu Li

Bank of America Securities

―

Hold

―

Reiterated

10/07/26

Analysts Conflicted on These Healthcare Names: Johnson & Johnson (NYSE: JNJ) and NeoGenomics (NASDAQ: NEO)

Matt Larew

William Blair

―

Hold

―

Reiterated

10/06/26

Analysts Conflicted on These Healthcare Names: Regeneron (NASDAQ: REGN) and NeoGenomics (NASDAQ: NEO)

David Westenberg

Piper Sandler

$21

Buy

20.90%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Equillium (EQ), NeoGenomics (NEO)

Mark Massaro

BTIG

$28

Buy

61.20%

Upside

Upgraded

10/06/26

NeoGenomics upgraded to Buy from Neutral at BTIGNeoGenomics upgraded to Buy from Neutral at BTIG

Michael Matson

Needham

$19→$22

Buy

26.66%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), AbbVie (ABBV)

Bruce Jackson

StoneX

$16→$20

Buy

15.14%

Upside

Reiterated

10/06/26

StoneX Sticks to Their Buy Rating for NeoGenomics (NEO)

William Bonello

Craig-Hallum

$17→$19

Buy

9.38%

Upside

Reiterated

07/29/26

NeoGenomics price target raised to $19 from $17 at Craig-HallumNeoGenomics price target raised to $19 from $17 at Craig-Hallum

Daniel Brennan

TD Cowen

$19

Buy

9.38%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Unknown Analyst

Stephens

Not Ranked

Stephens

$15.5

Buy

-10.77%

Downside

Reiterated

04/29/26

NeoGenomics (NEO) Receives a Buy from Stephens

Puneet Souda

Leerink Partners

$25

Buy

43.93%

Upside

Upgraded

04/29/26

NeoGenomics upgraded to Outperform from Market Perform at LeerinkNeoGenomics upgraded to Outperform from Market Perform at Leerink

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$15

Buy

-13.64%

Downside

Reiterated

02/18/26

Jefferies Sticks to Their Buy Rating for NeoGenomics (NEO)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

02/17/26

NeoGenomics (NEO) Receives a Hold from Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

OVIDOvid Therapeutics

ASNDAscendis Pharma

QNCXQuince Therapeutics

EHCEncompass Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NeoGenomics

3 Months

David WestenbergPiper Sandler

Success Rate

10/23 ratings generated profit

Average Return

+3.30%

Copying David Westenberg's trades and holding each position for 3 Months would result in 43.48% of your transactions generating a profit, with an average return of +3.30% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

12/21 ratings generated profit

Average Return

+18.40%

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +18.40% per trade.

2 Years

Daniel BrennanTD Cowen

Success Rate

13/21 ratings generated profit

Average Return

+27.00%

Copying Daniel Brennan's trades and holding each position for 2 Years would result in 61.90% of your transactions generating a profit, with an average return of +27.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NEO Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NEO has received 6 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NEO average Analyst price target in the past 3 months is 21.50.

Each month's total comprises the sum of three months' worth of ratings.

NEO Financial Forecast

NEO Earnings Forecast

Next quarter’s earnings estimate for NEO is $0.06 with a range of $0.04 to $0.07. The previous quarter’s EPS was $0.05. NEO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NEO has Performed in-line its overall industry.

NEO Sales Forecast

Next quarter’s sales forecast for NEO is $206.60M with a range of $203.90M to $209.00M. The previous quarter’s sales results were $201.66M. NEO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NEO has Performed in-line its overall industry.

NEO Stock Forecast FAQ

What is NEO’s average 12-month price target, according to analysts?

Based on analyst ratings, NeoGenomics’s 12-month average price target is 21.50.

What is NEO’s upside potential, based on the analysts’ average price target?

NeoGenomics has 23.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NEO a Buy, Sell or Hold?

NeoGenomics has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is NeoGenomics’s price target?

The average price target for NeoGenomics is 21.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $28.00 ,the lowest forecast is $19.00. The average price target represents 23.78% Increase from the current price of $17.37.

What do analysts say about NeoGenomics?

NeoGenomics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of NEO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

NeoGenomics (NEO) Stock Forecast & Price Target

NEO Analyst Ratings

NEO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering NeoGenomics

NEO Analyst Recommendation Trends

NEO Financial Forecast

NEO Earnings Forecast

NEO Sales Forecast

NEO Stock Forecast FAQ

Detailed List of Analyst Forecasts